News | March 06, 2024
Bayer aims to enhance performance and regain strategic flexibility by 2026
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
The acquisition of Healint aligns with Aptar Digital Health’s strategy to broaden its portfolio in neurology and strengthen its global footprint for digital health deployment
Sustainability is integral to Biocon's business purpose
The agreement sets terms under which POC will manufacture the product or receive royalties
iSolveSM information on demand is the result of our focus on customer relationship
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Subscribe To Our Newsletter & Stay Updated
